TerminatedPhase 1

A Phase 1 Study of MRTX0902 in Solid Tumors With Mutations in the KRAS MAPK Pathway

Stopped: business objectives have changed

United States64 participantsStarted 2022-12-02

Plain-language summary

This is a Phase 1, open-label, multicenter, study evaluating the safety, tolerability, PK, PD, and anti-tumor activity of MRTX0902 alone and in combination with MRTX849 (adagrasib) in patients with advanced solid tumor malignancy harboring mutations in the KRAS-MAPK pathways.

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. MRTX0902 monotherapy: known KRAS mutations, known annotated recurrent activating SOS1, PTPN11, class III BRAF, or EGFR mutation, or known annotated recurrent inactivating NF1 mutation;
✓. MRTX0902 and adagrasib combination therapy: KRAS G12C mutation.

What they're measuring

Number of Patients who Experience Dose-Limiting Toxicity

Timeframe: 21 Days

Number of patients who experience a treatment-related adverse event

Timeframe: Up to 2 years

Trial details

NCT IDNCT05578092

SponsorMirati Therapeutics Inc.

Sponsor typeINDUSTRY

Study typeINTERVENTIONAL

Primary completion2026-02-03

View on ClinicalTrials.gov More Solid Tumor trials